Pediatric Endocrinology · Grand Rounds
Deep Physiology of
Hunger & Satiety
— and the clinical approach to obesity.
Emad Miyajan
Pediatric Endocrinology Fellow
King Fahad Medical City
One patient — Layan, 13 — threads the whole talk; we return to her as each mechanism unfolds.
Opening. Welcome. Tonight we travel from a single hunger-signalling molecule up to the clinic — how hunger starts, how a meal stops, why obesity develops, and where every therapy acts on that same circuit.
- One idea to carry through: appetite is a regulated biological system, not willpower.
- Transition: start with a patient who is still hungry after eating.
01
The Core Question
We’re about to meet Layan — still hungry after she eats. First we define the terms: what hunger is, on what timescales it acts, and the whole system that decides when — and how much — we eat.
The Core Question
Microphysiology of Hunger
How a Meal Stops
Hypothalamic Integration
Why Obesity Develops
Clinical Approach
Breaking the Cycle
Pharmacotherapy
Surgery
Section 1 of 9. We define our terms precisely — because hunger, appetite, satiation, and satiety are distinct clinical entities that too often get collapsed into one word.
Meet Layan — 13, with rapid weight gain
She finishes a full meal, then asks for more within the hour. Snacks constantly. Her parents describe “no off-switch.” We meet her properly on the next slide.
The reflexive read: a discipline problem.
But the same complaint appears across unrelated children, families, and cultures — which points away from character and toward biology.
Reframe
Hunger is a brain state driven by signals
- Peripheral signals from gut, fat, and pancreas…
- …are integrated by the hypothalamus…
- …and can be overridden by reward circuits.
When those signals mis-fire or are resisted, hunger persists despite adequate intake. That is the story of this deck.
Framing question
If hunger is biology, then treatment must target the biology — not the willpower.
Teaching message: anchor the whole lecture in a relatable patient. The persistence of hunger despite eating is the hook.
- Nuance: avoid moralising language with families; it damages the therapeutic alliance and is scientifically wrong.
- Misconception to correct: “eats too much = lacks discipline.”
- Transition: to treat it we first need shared vocabulary — hunger vs appetite vs satiation vs satiety.
Layan · girl, 13 y 2 m
Rapid weight gain over ~2 years. Height 157 cm · weight 95 kg.
38.5
BMI kg/m²
Class 3 severe obesity
≈146% of the 95th pct
BMI-for-age > 99th
History
- Persistent hunger — “no off-switch” after full meals; grazing / night eating.
- Repeated diet attempts followed by weight regain.
- ~6 h sleep + evening screens; low activity; daily sugar-sweetened drinks / juice.
Exam
- Acanthosis nigricans; narrow pale striae (obesity-associated — not wide violaceous).
- High-normal BP; Tanner-appropriate puberty; normal linear growth.
- No syndromic or Cushingoid features.
BMI-for-age (CDC 2000, girls)
Family & labs
- Family: mother T2DM · father obesity · grandmother T2DM.
- HbA1c 6.0% (prediabetes) · TG↑ / HDL↓ · TSH normal.
- ALT ~60 → suspicion for MASLD (needs confirmation & exclusion of other liver disease).
Diagnostic framing · probabilistic
Most consistent with common polygenic obesity — no current strong red flags for early-onset monogenic / secondary forms. Genetic & secondary work-up stays guided by hyperphagia, true onset age, family history, growth and clinical signs.
Teaching message: Layan turns the abstract complaint into one patient we will follow through the whole deck — the physiology, the work-up, and every therapy map back onto her.
- Classification: BMI 38.5 at 13 y 2 m ≈ 146% of the CDC 95th percentile (z ≈ 2.55, >99th) → Class 3 severe obesity (≥140% of 95th, or BMI≥35–40). Single clear class — never “class 2–3”.
- Striae wording matters: narrow pale striae are expected with rapid adiposity; wide violaceous striae would raise Cushing — hers are not. Normal linear growth is recorded as an observation, not a definitive rule-out.
- ALT: say “elevated ALT raising suspicion for MASLD requiring confirmation, longitudinal assessment and exclusion of alternative liver disease” — never “ALT 60 = MASLD”.
- Humility: monogenic/secondary causes are not excluded — the evaluation stays guided by phenotype. Avoid single-cause language.
- Transition: to understand why her off-switch fails, we first need shared vocabulary — hunger vs appetite vs satiation vs satiety.
Hunger
An internal brain state produced by physiological signals of energy need.
Appetite
The desire or readiness to eat — shaped by internal and external cues.
Satiation
Short-term processes that end the current meal — the feeling of fullness during eating.
Satiety
Longer-term processes that delay the next meal — how long fullness lasts afterward.
Craving
A strong, specific desire for a particular food — can occur without any energy need.
Liking vs Wanting
Liking = pleasure from food. Wanting = the drive to obtain it. They are separable in the brain.
Key idea
Hunger is a brain state · Satiation ends the meal · Satiety delays the next one.
Teaching message: precision here pays off all lecture. Satiation ≠ satiety is the single most useful distinction for drug mechanisms later.
- Nuance: wanting (dopaminergic) can be high while liking is normal — central to reward-driven eating.
- Transition: these processes each run on their own clock — seconds to days.
Seconds
Rapid brain & gut responses begin the moment food is seen or tasted.
Minutes
Satiation builds during the meal — distension and gut hormones accumulate.
Hours
Satiety rises gradually after the meal ends, setting the inter-meal interval.
Days
Adipose signal leptin (with insulin as a meal-linked co-signal) regulates hunger and satiety over the long run.
Pre-meal
Hunger & appetite overcome us before eating — largely a fasting and anticipation signal.
During meal
Satiation starts and terminates the current meal — it determines meal size.
Post-meal
Satiety emerges and delays the next meal — it determines meal frequency.
Teaching message: different timescales = different therapeutic targets. GLP-1 drugs act on the minutes-to-hours window (satiation + satiety); leptin biology is the days-and-longer window.
- Audience question: “Which clock does a rapid eater outrun?” (the minutes clock — calories arrive before satiation develops).
- Transition: now the whole wiring diagram.
Inputs · click an organ
Afferent signal → brain target
Ghrelin+Distension−SignalPre-meal ghrelin drives hunger — the lone “+”. Mechanical distension during eating signals fullness.
Brain targetDistension: vagus → NTS. Ghrelin: bloodstream → GHSR (hypothalamus & brainstem).
CCK
GLP-1
PYY−SignalNutrient sensing releases CCK, GLP-1, PYY — satiety (−) signals that end the meal and delay the next.
Brain targetBloodstream → ARC (PYY/GLP-1); CCK via vagal afferents → NTS / area postrema.
Insulin
Amylin−SignalInsulin and amylin act as meal-linked satiety (−) signals, released in proportion to the meal.
Brain targetCirculation → hypothalamus (ARC); amylin also → area postrema.
Leptin−SignalLeptin reports long-term fat stores — a tonic (−) adiposity signal suppressing appetite when stores are ample.
Brain targetCirculation → ARC (POMC ↑ / AgRP ↓).
Sight · smell · palatability+
SignalSensory food cues drive a feed-forward (+) anticipatory response — before any nutrient arrives.
Brain targetReward circuits — VTA → nucleus accumbens (hedonic pathway).
Brain integration hubs
NTS & Area postrema
Hypothalamus · ARC / PVN
Reward circuits · VTA, NAc (hedonic pathway)
Outputs
- Meal initiation / termination
- Food-seeking behaviour
- Energy expenditure
- Autonomic & endocrine responses
+ Stimulatory
− Inhibitory
Neural relay (vagus)
Hormonal circulation
Feed-forward prediction
Teaching message: this is the master diagram — every later slide zooms into one arrow of it. Note ghrelin is the lone “+”; nearly every other gut/adipose signal inhibits intake.
- Nuance: negative feedback (adiposity → leptin/insulin → ↓appetite) plus feed-forward (cues → prediction before nutrients arrive).
- Transition: zoom into the pre-meal state and the ghrelin signal.
Time since last meal
3 h
Fed · 0h←→Fasted · 18h
Hunger meter
Satiated
23
/ 100
GhrelinGLP-1PYYCCKInsulin
AgRP/NPY · GO-EAT
POMC/α-MSH · STOP-EATWhat's driving the drive to eat
Just ate — satiety signals high, ghrelin low.
Interactive teaching: drag from Fed to Fasted. As the fast lengthens, ghrelin and the AgRP/NPY "go-eat" neurons climb while every satiety signal (GLP-1, PYY, CCK, insulin) and the POMC "stop-eat" neurons fall — and the hunger meter rises with them. Hunger isn't willpower; it's a hormonal state set by when you last ate.
02
Microphysiology of Hunger
To trace Layan’s pre-meal hunger to its source: ghrelin is acylated, travels to the hypothalamus, and switches on the neurons that make us seek food.
The Core Question
Microphysiology of Hunger
How a Meal Stops
Hypothalamic Integration
Why Obesity Develops
Clinical Approach
Breaking the Cycle
Pharmacotherapy
Surgery
Section 2 of 9. The flagship pathway. Walk it one step at a time — each “Next” advances the ghrelin cascade before moving on.
Empty stomach
Fasting drives ghrelin secretion by the stomach and duodenum.
Des-acyl ghrelin
Produced first as des-acyl ghrelin — a homeostatic signal that does not activate the ghrelin receptor (GHSR); GOAT acylation is required for its orexigenic action.
GOAT acylation
The enzyme GOAT adds an octanoyl group → active acyl-ghrelin.
GHSR
Acyl-ghrelin travels in the blood to GHSR in the hypothalamus & brainstem (VMH GHSR → positive energy balance).
Caveat
Ghrelin is a meal-anticipation & fasting signal — not the sole cause of hunger. Many signals and circuits interact.
Back to Layan: pre-meal ghrelin is one mechanism that may sharpen anticipatory hunger in a similar phenotype — not the sole cause of her “no off-switch.”
Teaching message: the canonical ghrelin production pathway — stomach to receptor. Acylation by GOAT is the activating step, a genuine drug target of interest.
Intracellular cascade
Gq/11
↓
PLC
↓
IP₃ / DAG
↓
↑ intracellular Ca²⁺
AgRP / NPY neuron fires
Rising calcium activates the arcuate AgRP/NPY neurons — the master “go-eat” cells.
NPYVia Y1/Y5 receptors → promotes eating & energy storage
GABAInhibitory co-transmitter (dampens anorexigenic neurons)
AgRPCompetitive antagonist of MC4R (& MC3R)
Food-seeking
The integrated output is a powerful, negative-valence hunger state that prioritises finding and eating food.
Teaching message: what acyl-ghrelin does inside the arcuate neuron — Gq/11 → PLC → IP₃/DAG → rising Ca²⁺ activates AgRP/NPY, producing an aversive, food-seeking drive.
- Nuance: AgRP-neuron activity encodes an aversive state — hunger feels bad, which is motivationally powerful.
- Misconception: “ghrelin = hunger.” It is one input among many.
- Transition: what those AgRP outputs do, and how fast cues switch them off.
Three outputs, one goal
NPY → Y1/Y5 receptors promote eating and energy storage (adipogenesis).
GABA → inhibitory co-transmitter that dampens anorexigenic (POMC) neurons.- AgRP → competitive antagonist of MC4R (& MC3R); lifts the appetite brake and lowers SNS-driven thermogenesis.
Net effectFood-seeking & increased appetite
Feed-forward prediction
Cues switch hunger off before calories arrive
The mere sight or smell of food rapidly suppresses AgRP-neuron activity — within seconds, long before any nutrient is absorbed.
Sensory cue
Prediction
↓ AgRP
Why it matters
The brain predicts and pre-empts — so an obesogenic cue environment can drive eating with no true energy deficit.
Teaching message: feed-forward suppression shows the system is predictive, not merely reactive. It also explains cue-driven eating clinically.
- Audience question: “Why do we feel less hungry the instant a meal is served?” → anticipatory AgRP suppression.
- Transition: when prediction and reward override homeostasis.
Reward & motivation circuits
VTA → dopamine
Wanting — motivation to obtain food
Nucleus accumbens
Hedonic pathway hub
Opioid systems
Liking — pleasure of eating
Amygdala
Stress & emotional salience
Modulators that shift eating up
- Stress → ↑ cortisol
- Sleep deprivation → ↑ ghrelin, ↓ leptin
- Repeated cue exposure → learned associations strengthen
Homeostatic eating
Body energy signals maintain balance
vs
Cue-driven eating
Reward & learning override hunger/satiety
Take-home
Patients may eat in the absence of energy need because reward and cues can override homeostatic signals.
Teaching message: two parallel systems — homeostatic and reward. Modern food environments supercharge the reward arm.
- Nuance: “wanting” can escalate with repeated exposure even as “liking” stays flat — the hallmark of cue-driven overeating.
- Transition: now the opposite question — how does a meal actually stop?
03
How a Meal Stops
Layan describes “no off-switch” — so here are the two switches: satiation ends the meal in progress, satiety keeps you from eating again too soon. Two clocks, two clinical levers.
The Core QuestionMicrophysiology of Hunger
How a Meal StopsHypothalamic Integration
Why Obesity DevelopsClinical Approach
Breaking the CyclePharmacotherapySurgery
Section 3 of 9. Satiation is the process most GLP-1 therapies amplify — worth building carefully.
1 · Cephalic
Sight/smell/taste pre-activate the brain & gut.
2 · Oral
Chewing, texture & eating rate release early hormones.
3 · Distension
Gastric stretch activates mechanoreceptors.
4 · Nutrient sensing
I-cells detect nutrients and release CCK
5 · Vagus → NTS
CCK1 receptors on vagal afferents signal the brainstem.6 · Meal ends
Early fullness & termination of eating.
Classic satiation signal
Gastric distension + CCK = the core meal-termination duo.
Why eating rate matters
Rapid eating delivers calories faster than satiation signals can develop — so more is eaten before “full” registers.
Key point
Satiation determines meal size — which is exactly the lever slower eating and gut-hormone drugs pull.
Teaching message: a mechanoreceptor + chemoreceptor story converging on the vagus and NTS. CCK is the prototype meal-ending hormone.
- Nuance: eating rate is a modifiable behaviour with real physiology behind it — not just etiquette.
- Clinical link: GLP-1 agonists slow gastric emptying and amplify this exact loop.
- Transition: after the meal ends, why don’t we eat again immediately?
Gut & pancreatic satiety signals
GLP-1 → GLP-1R 
−
PYY → Y2R 
−
Insulin → insulin receptor −
Amylin → amylin receptor −
GLP-1 → GLP-1R −PYY → Y2R −Insulin → insulin receptor −Amylin → amylin receptor −Released from intestinal L-cells and the pancreas, these act on the hypothalamus and area postrema / NTS to prolong fullness.
Intestine · L-cells
Pancreas
Physiological & behavioural outcomes
- Delayed gastric emptying ↓
- Reduced hunger ↓
- Smaller next meal ↓
- Longer inter-meal interval ↑
Time course
15–30 min
1–3 hours
3–6 hours
Satiety builds and decays over the whole post-meal window.
Bottom line
Satiation ends the current meal · Satiety prevents early re-feeding.
Teaching message: satiety is the durable signal that sets meal frequency. GLP-1 and PYY are the headliners — and the pharmacological targets.
- Nuance: endogenous GLP-1 has a very short half-life; drugs are engineered to resist degradation.
- Transition: put satiation and satiety side by side.
Satiation
- When: during the meal
- Does: terminates eating
- Sets: meal size
- Drivers: distension, CCK, oral factors, eating rate
- Clock: minutes
Satiety
- When: after the meal
- Does: delays the next meal
- Sets: meal frequency
- Drivers: GLP-1, PYY, insulin, amylin
- Clock: hours
Clinical translation
Shrink the meal → target satiation. Stretch the gap between meals → target satiety. Modern drugs do both.
Teaching message: a two-column mental model students remember. Map behaviours and drugs onto each column.
- Audience question: “A drug that makes portions smaller acts on which one?” (satiation).
- Transition: upstairs to the hypothalamus, where all of this is integrated.
04
Hypothalamic Integration
Where all of Layan’s signals are weighed: in the arcuate nucleus two neuron populations compete, and hormones from fat and pancreas tip the balance — with built-in brakes.
The Core QuestionMicrophysiology of Hunger
How a Meal StopsHypothalamic Integration
Why Obesity DevelopsClinical Approach
Breaking the CyclePharmacotherapySurgery
Section 4 of 9. The integration hub. Set up the AgRP-vs-POMC tug-of-war before layering leptin and insulin onto it.
A window to the blood
The ARC sits in the medial basal hypothalamus, where fenestrations in the blood–brain barrier let it directly sample circulating signals — leptin, insulin, ghrelin, PYY, glucose.
First-order sensors
Two neuron populations read those signals:
POMC / CART — catabolic (anorexigenic)AgRP / NPY — anabolic (orexigenic)
Second-order relay
First-order neurons project to the PVN & lateral hypothalamus, acting through melanocortin receptors MC4R & MC3R to set a net catabolic ↔ anabolic drive.
A gated integrator
Peripheral signals are summed here into a single “go-eat / stop-eat” decision — losing MC4R alone causes severe hyperphagia and obesity.
Teaching message: the ARC is the first-order integration hub of a gated neural circuit (Sperling p.943–945). Its median-eminence location with fenestrated BBB lets it sense blood-borne hormones directly; POMC/CART (catabolic) and AgRP/NPY (anabolic) neurons project to second-order PVN/LHA neurons via MC4R/MC3R. Smooth entry: introduce the hub here, then the next slide opens up the two competing populations in detail.
- Anchor: MC4R-null mice display severe hyperphagia and obesity (p.944) — the strongest single-gene proof of this node's importance.
+
AgRP / NPY / GABA
Increases appetite. The “go-eat” population — active in fasting, driven by ghrelin.
Releases AgRP (competitively antagonises MC4R), NPY (Y1/Y5), and GABA (inhibits POMC).
−
POMC / CART
Decreases appetite. The “stop-eat” population — activated when energy is plentiful.
POMC is processed to α-MSH, the key output peptide.
The melanocortin axis
POMC → α-MSH → MC4R is the master appetite brake — and the target of the newest precision drug, setmelanotide.
Teaching message: the ARC is a balance beam. AgRP antagonises MC4R; POMC-derived α-MSH activates it. This single receptor recurs in genetics and pharmacology.
- Nuance: monogenic obesity often maps onto this exact pathway (POMC, MC4R, LEPR).
- Transition: what tips the balance? Leptin from fat.
Adipose ↑
More fat mass → more leptin secreted
LepRb
Leptin crosses to the brain and binds LepRb.
JAK2 / STAT3
Intracellular signalling is switched on.
↑POMC · ↓AgRP
Tips the ARC toward the satiety population.
↓ appetite
α-MSH → MC4R → appetite falls, expenditure rises.
→ appetite falls, expenditure rises.
Insulin runs in parallel
Insulin
POMC↑ · AgRP↓
↓ appetite
Built-in brake
SOCS3 is an intracellular negative-feedback molecule that limits leptin signal transduction — an autoregulatory “stop.”
The logic
Leptin is a “fuel gauge,” not a satiety-per-meal hormone — it defends long-term energy stores.
Teaching message: leptin is negative feedback on adiposity. The JAK2/STAT3 arm is central; SOCS3 sets the gain and previews leptin resistance.
- Nuance: exogenous leptin fails in common obesity precisely because signalling — not leptin level — is the problem.
- Transition: so what goes wrong? Leptin resistance.
Hyperleptinemia
Obesity → chronically high circulating leptin.
Impaired transport
Less leptin crosses into the brain (BBB).
Impaired signalling
SOCS3 ↑ (autoregulatory) blunts the LepRb response.
Hypothalamic inflammation
Inflammation, gliosis & ER stress impair leptin responsiveness.
The trap
The brain reads a low-leptin (starvation) state despite abundant fat — so it lowers resting energy expenditure and keeps hunger high, defending the weight.
Back to Layan
Defended-weight biology like this is one mechanism that may help explain why prior diets were followed by regain in patients with a similar phenotype — context for her failed attempts, not a judgement on effort.
Reframe
Obesity is a state of impaired signalling, not absent hormone — which is why “just eat less” fights the brain’s own thermostat.
Teaching message: leptin resistance is the molecular bridge to “defended weight.” High leptin + poor signalling = brain perceives deficit.
- Misconception: “obese patients lack leptin.” The opposite — they’re resistant to it.
- Transition: zoom out to why obesity develops and why weight comes back.
Body fat mass
30%
low←→high
Hunger drive
5/100
Brain reads: plenty of fat → suppress appetite
Leptin producedLepRb brain signalingHunger driveLeptin is the body's "fat is plentiful" signal. It must reach LepRb in the hypothalamus to turn hunger down.
Why obesity defends its weight
Healthy feedback: fat → leptin → brain → less hunger.
Interactive teaching: raise fat mass and leptin climbs. With resistance OFF the brain hears it (LepRb high) and hunger falls — healthy negative feedback. Flip resistance ON: leptin stays high but LepRb signaling collapses, so the brain misreads high fat as starvation and keeps hunger up. This is the leptin-resistance trap that makes obesity a defended state, not a willpower failure.
05
Why Obesity Develops
Why Layan regained after each diet: obesity is multifactorial, and — critically — the body actively defends a raised weight. Regain is biology, not a lapse of willpower.
The Core QuestionMicrophysiology of Hunger
How a Meal StopsHypothalamic Integration
Why Obesity DevelopsClinical Approach
Breaking the CyclePharmacotherapySurgery
Section 5 of 9. The conceptual heart for clinicians: defended weight and the regain loop reframe how we counsel families.
Genetic susceptibility
Sets the biological baseline and how strongly weight is defended.
Food environment
Cheap, abundant, hyper-palatable food and relentless cues.
Reward & cue pressure
Learned cue–reward associations push intake beyond need.
Sleep & inactivity
Short sleep raises ghrelin, lowers leptin; low activity lowers expenditure.
Leptin resistance
The brain misreads energy stores and keeps hunger elevated.
Chronic positive balance
The sustained net result: intake exceeds expenditure over the long run.
Frame for families
Obesity is a chronic, multifactorial disease — understanding the biology is the key to effective, durable treatment.
Teaching message: no single cause. Genetics loads the gun; environment pulls the trigger; neurobiology sustains it.
- Nuance: the same environment produces very different outcomes across genotypes — hence “phenotype before prescribing” later.
- Transition: the most counter-intuitive part — why weight comes back.
Weight-regain pressure
Weight loss
the trigger
Fat mass ↓
Leptin ↓
insulin ↓ · ghrelin ↑
Hunger & cravings ↑
~+100 kcal/d per kg lost
Expenditure ↓
resting + NEAT
Food preoccupation ↑
Defended body-weight range
Your body defends a range, not a number
Fall below it and counterregulatory mechanisms — hunger up, expenditure down — actively push you back toward the defended range.
Weight-loss adaptation is a biological defense, not poor willpower.
What-if · the deeper the cut, the harder the defense
Hunger↑
Expenditure↓
Projected regain pressure: Moderate
Back to Layan: this loop is one mechanism that may contribute to her post-diet regain — biology and environment together.
Teaching message: the single most important reframe for patients. Walk the loop arc by arc; land on “defended range.”
- Nuance: adaptive thermogenesis + hormonal shifts persist long after weight loss.
- Misconception to correct: “regain = the patient gave up.”
- Transition: this is also why a plateau isn’t drug failure.
Daily intake
2000 kcal
500 · deep deficit2000 · maintenance3500 · surplus
State: Energy balance — hormones steady
Projected weight · 12 weeksstable
At maintenance, weight holds steady.
LeptinGhrelinInsulinThyroid T3 (leptin-driven)Energy expenditureHunger drive
The body defends its weight
Cut calories and the body fights back — hunger rises while metabolism slows, so loss plateaus. This is why sustained weight loss needs more than willpower.
Interactive teaching: let the audience drive the slider. Below maintenance, the fall in leptin (Sperling p.943, 948) drives the counterregulatory response — ghrelin/hunger rise, insulin falls, and the leptin-driven fall in T3 lowers thermogenesis/expenditure — so the weight curve bends toward a plateau. Above maintenance, the mirror image (storage). Ties directly to "a plateau is biology, not failure." (T3's role in adaptive thermogenesis is standard physiology beyond the Sperling chapter, which frames the slowdown via leptin/REE.)
06
Clinical Approach
Now Layan is in front of us. From the first visit onward: confirm, assess drivers, screen, rule out mimics, examine, investigate, and personalise.
The Core QuestionMicrophysiology of Hunger
How a Meal StopsHypothalamic Integration
Why Obesity DevelopsClinical Approach
Breaking the CyclePharmacotherapySurgery
Section 6 of 9. The practical pivot. This is the framework fellows can take to clinic tomorrow.
1Confirm severity
BMI percentile by age/sex · class 1/2/3 · growth trajectory.
2Assess drivers
Biology, environment, family, sleep, medications, psychology.
3Screen complications
T2DM, MASLD, dyslipidemia, HTN, OSA, PCOS, MSK, mental health.
4Rule out mimics
Red flags → targeted testing and/or specialist referral.
5Intensive lifestyle
Family-based behavioural treatment — the foundation.
6Add pharmacotherapy
When indicated — age-appropriate agent + lifestyle.
7Refer for surgery
Severe, persistent disease or major comorbidity, in expert centres.
ReassessContinuous reassessment & adjustment based on response.
Multidisciplinary care · family partnership
Evidence-based · measurable outcomesGoal: healthier today, better tomorrowTeaching message: a staged, reassessing framework — not a one-shot decision. Lifestyle underlies every tier, including drugs and surgery.
- Clinical pearls: obesity is a chronic disease; treat early to change trajectory; know the phenotype before prescribing; aim for function and durable behaviour change, not just the scale.
- Transition: it all starts with the history.
1Weight trajectory
- Onset age
- Rapid acceleration (Layan: over ~2 y)
- Previous plateaus & interventions
2Eating phenotype
- Hunger / satiety (Layan: "no off-switch")
- Binge / loss of control
- Night & emotional eating
- Cues, sugary drinks (Layan: night eating, daily SSBs)
3Lifestyle & environment
- Sleep & screen time (Layan: ~6 h + screens)
- Physical activity
- School / family meals
- Food availability, stress
4Medical history
- Hypothalamic injury
- Endocrine symptoms
- Developmental delay
- OSA symptoms, constipation, reflux, headaches
5Medication review
- Steroids
- Atypical antipsychotics
- Valproate, insulin, sulfonylureas
- Some antidepressants / antiepileptics
6Family history
- Obesity, T2DM (Layan: mother & grandmother T2DM, father obesity)
- Dyslipidemia, HTN
- PCOS, early CV disease
- Genetic syndromes
Red flags in the history
Onset < age 5 with severe hyperphagia · poor linear growth · headaches/visual symptoms · polyuria/polydipsia · developmental delay · dysmorphic/syndromic features.
Teaching message: a structured history separates common obesity from secondary/monogenic causes. The red-flag row is the safety net.
- Nuance: medication-induced weight gain is common and reversible — always reconcile the med list.
- Transition: the focused physical exam.
Vitals & growth
- BMI ↑
- Waist circumference (optional)
- Blood pressure (Layan: high-normal)
- Height velocity (Layan: normal linear growth — an observation, not a rule-out)
- Pubertal (Tanner) stage
Signs to seek
- Skin: acanthosis nigricans, striae, hirsutism, skin tags (Layan: acanthosis present; narrow pale striae — not wide violaceous)
- Head/neck: tonsillar hypertrophy, thyroid, papilledema
- MSK: genu valgum, SCFE clue, Blount, joint pain
- Abdomen: hepatomegaly (MASLD)
Suspect secondary obesity
- Short stature / poor height velocity
- Delayed puberty
- Cushingoid features (Layan: narrow pale striae → less likely, not excluded)
- Neurologic symptoms
- Severe early hyperphagia
- Dysmorphism
Common / expected Needs further evaluation Red flag (urgent)Teaching message: the exam is a comorbidity-and-mimic hunt. Psychosocial screening (depression, disordered eating, bullying, QoL) is part of the exam, not an afterthought.
- Nuance: SCFE and Blount are “can’t-miss” orthopedic complications of pediatric obesity.
- Transition: which investigations, and when.
Red flags — absent- No extreme early-onset (< 5 y) hyperphagia
- No developmental delay, dysmorphism or syndromic features
- Normal linear growth — not slowing
- No wide violaceous striae / Cushingoid habitus
- No polyuria, polydipsia or symptomatic hyperglycaemia
- No headache / visual change; no obesogenic medication
Concerning — present- Acanthosis nigricans — a marker of insulin resistance
- Strong family T2DM (both sides) + parental obesity
- Prediabetes (HbA1c 6.0%) + dyslipidaemia (TG↑/HDL↓)
- Elevated ALT → MASLD suspicion (needs confirmation)
- Hyperphagia “no off-switch”, night eating, daily SSBs
- Short sleep (~6 h) + high screen time
Reading the screen
Absent red flags lower the probability of monogenic / secondary disease — they do not exclude it. Present findings point to common polygenic obesity with early metabolic complications, which shapes both the work-up and the treatment order.
Teaching message: a real approach narrates the pertinent positives and negatives out loud. The absent red flags (early extreme onset, dysmorphism, growth failure, violaceous striae, symptomatic hyperglycaemia, obesogenic drugs) make classic monogenic/secondary causes less likely — but "less likely" is not "excluded"; the genetic/secondary work-up stays guided by phenotype and is revisited over time. The present findings — acanthosis, family T2DM, prediabetes, dyslipidaemia, MASLD suspicion, hyperphagia, poor sleep — define her as common polygenic obesity that has already started to generate metabolic complications, and it is those complications (rising glycaemia + acanthosis) that will drive the first medication choice.
Staging- BMI 38.5 kg/m² (95 kg / 1.57²)
- ≈146% of the 95th percentile (CDC 2000)
- → Class 3 severe obesity — one clear class
- Normal linear growth — recorded as an observation, not a rule-out tool
Diagnostic read- Picture most consistent with common polygenic obesity
- No current strong red flags for classic monogenic / secondary forms
- Genetic & secondary work-up remains guided — not excluded
- ALT ~60 → suspicion of MASLD requiring confirmation & longitudinal assessment
Tier decisionIntensive lifestyle · the foundation under every tier
Eligible for pharmacotherapy · Class 3 + age ≥ 12 y, added to lifestyle
Bariatric referral criteria discussed · adolescent Class 3 pathway
Clinical humility
Severity is one clear Class 3; the cause is probabilistic — treat the phenotype now, keep the secondary work-up guided, and reassess.
Teaching message: staging is the bridge from numbers to a plan. Layan's ≈146% of the 95th percentile places her firmly in Class 3, which — with age ≥ 12 — makes her eligible for pharmacotherapy on top of the lifestyle foundation, and puts bariatric referral criteria on the table for discussion. The specific drug decision is the next slide.
- Language: "most consistent with polygenic obesity" is a probability, not a verdict — monogenic/secondary causes are guided by phenotype, never declared excluded.
- ALT: an elevated ALT raises suspicion for MASLD; it is not itself a diagnosis and needs confirmation, longitudinal assessment, and exclusion of alternative liver disease.
- Transition: choosing the agent — approved adolescent options vs emerging/off-label.
07
Breaking the Cycle
Where Layan’s plan begins — before drugs: the physiological levers of lifestyle, each targeting a specific node of the cycle we just mapped.
The Core QuestionMicrophysiology of Hunger
How a Meal StopsHypothalamic Integration
Why Obesity DevelopsClinical Approach
Breaking the CyclePharmacotherapySurgery
Section 7 of 9. Lifestyle is not the “weak” option — it is the mechanistic foundation every drug and surgery builds on.
Protein
↑ satiety, ↓ reactive hunger
Fiber / volume
↑ fullness, slows gastric emptying
Slower eating rate
Lets satiation signals catch up
Sleep
↓ ghrelin, supports leptin signalling
Physical activity
↑ insulin sensitivity · 30 min vigorous ×5/wk
Family-targeted therapy
Larger BMI fall than targeting the child alone
The evidence-backed core
- Eliminate sugar-sweetened beverages & juice; low-glycemic-load diet
- Motivational interviewing to work through ambivalence
- Fewer food cues & stimulus control at home
Realistic, sustainable goals
For most children the target is weight maintenance, not loss · health markers improve · durable habits — not just a number on the scale.
Teaching message: connect each lever back to a mechanism from earlier sections — protein/fiber→satiation, sleep→ghrelin/leptin, activity→insulin sensitivity.
- Nuance: preserving lean mass matters, especially alongside potent pharmacotherapy.
- Transition: what patients actually feel when this works.
Less reactive hunger
Hunger intrudes less on the day
Longer satiety
Fuller for longer after meals
Fewer cravings
Less “food noise”
Better control around food
Less unplanned snacking
Improved energy
More activity feels possible
Name the trade-offs
Early GI upset, fatigue during calorie reduction
Precision matters
Distinguish therapeutic satiety from nausea, food aversion, delayed emptying, or true appetite loss. Not all reduced intake is healthy satiety.
Teaching message: patient-centred language you can reuse in counselling. The final caveat is clinically vital when drugs enter the picture.
- Nuance: weight loss driven by nausea/aversion is not the goal and can signal intolerance.
- Transition: now the pharmacology — where each drug acts on the circuit.
08
Pharmacotherapy
If lifestyle alone can’t hold Layan’s defended weight: each drug breaks a specific node of the cycle. Know where it acts, what she would feel, and — crucially — the pediatric approval status.
The Core QuestionMicrophysiology of Hunger
How a Meal StopsHypothalamic Integration
Why Obesity DevelopsClinical Approach
Breaking the CyclePharmacotherapySurgery
Section 8 of 9. Start with the interactive map — click each agent to see where it acts — then deep-dive the key drugs. Always separate pediatric diabetes approval from pediatric obesity approval.
Metformin Insulin sensitiser
Acts whereLiver, muscle, gut — not primarily the brain
Signal change↓ hepatic glucose output · ↑ insulin sensitivity · ↓ hyperinsulinemia
Breaks cycle atThe insulin-resistance node
Patient feelsModest appetite reduction in some; early GI upset that often improves
Pediatric statusUsed, often off-label for obesity alone; helpful when IR/PCOS/T2DM coexist
Not a potent anti-obesity drug
Liraglutide GLP-1 RA
Acts whereGut–brain axis · hypothalamus · stomach
Signal change↑ satiety · ↓ hunger · slows gastric emptying · ↓ food preoccupation
Breaks cycle atThe hunger & satiety node
Patient feelsSmaller portions, earlier fullness, less snacking; possible nausea
Pediatric statusSaxenda — pediatric obesity, age 12+ (weight >60 kg & obesity)
Boxed warning: thyroid C-cell tumors (MTC/MEN2)
Semaglutide GLP-1 RA
Acts whereGut–brain axis · hypothalamus · stomach
Signal change↑ satiety · ↓ hunger · slows gastric emptying · improved glucose control
Breaks cycle atThe hunger & satiety node — potently
Patient feelsMarkedly smaller portions, less “food noise”; possible nausea
Pediatric statusWegovy — pediatric obesity, age 12+. Ozempic ≠ Wegovy (diabetes brand)
Boxed warning: thyroid C-cell tumors (MTC/MEN2)
Tirzepatide GIP + GLP-1
Acts whereDual GIP & GLP-1 receptors · appetite circuits · stomach
Signal changeStronger satiety (dual activation) · ↓ hunger · slower emptying · ↑ insulin sensitivity
Breaks cycle atHunger/satiety + insulin-resistance nodes together
Patient feelsStrong early fullness, reduced drive to eat; GI effects common
Pediatric statusMounjaro (T2DM, ≥10 y) · Zepbound (obesity, adults). Pediatric obesity approval ≠ pediatric T2DM approval
Boxed warning: thyroid C-cell tumors (MTC/MEN2)
Orlistat GI lipase inhibitor
Acts whereGut lumen — intestinal lipase
Signal change↓ dietary fat absorption (~30%)
Breaks cycle atEnergy absorption — not the central drive
Patient feelsOily stool, urgency, flatulence (dose/diet dependent)
Pediatric statusUsed in adolescents; needs fat-soluble vitamin supplementation
Does not target hunger circuits
Phentermine / Topiramate ER Central
Acts whereCentral appetite circuits
Signal change↓ appetite & food-seeking · ↑ satiety
Breaks cycle atCentral drive & reward pressure
Patient feelsReduced appetite; paresthesia, dry mouth, mood/cognitive effects possible
Pediatric statusPediatric obesity indication age 12+
Teratogenic — avoid in pregnancy
Setmelanotide MC4R agonist
Acts whereMC4R, downstream in the melanocortin pathway
Signal changeRestores appetite suppression when upstream signalling is lost
Breaks cycle atThe melanocortin node — precision therapy
Patient feelsReduced pathologic hunger, less constant food drive
Pediatric statusSelected rare obesities: POMC, PCSK1, LEPR deficiency, Bardet–Biedl, acquired hypothalamic obesity (per labeling)
Injection-site reactions · hyperpigmentation
Bariatric surgery Metabolic
Acts whereStomach + gut hormones — not just size
Signal change↓ ghrelin · ↑ GLP-1 & PYY · altered bile acids · ↑ insulin sensitivity
Breaks cycle atMultiple nodes at once
Patient feelsEarly reduced appetite, rapid satiety, smaller comfortable meals
Pediatric statusAdolescents ≥13 with severe obesity in experienced centres; lifelong follow-up
Metabolic therapy, not mechanical restriction alone
Teaching message: the organising visual for pharmacology — every drug maps to a node of the cycle. Demonstrate 2–3 live clicks (metformin vs semaglutide vs surgery) to show the contrast in where they act.
- Critical safety point: pediatric diabetes approval ≠ pediatric obesity approval; brand ≠ molecule.
- Transition: deep-dive the workhorses, starting with metformin.
Mechanism (how it helps)
- ↓ hepatic glucose production (liver)
- ↑ insulin sensitivity (muscle & periphery)
- Modestly ↓ appetite in some patients
- May help IR, PCOS, prediabetes
Not a potent anti-obesity drug on its own
Dosing & titration
- Start 500 mg with the evening meal
- Then 500 mg twice daily
- ↑ by 500 mg every 1–2 weeks as tolerated
- Typical target 1000 mg twice daily
ER option: up to 2000 mg once daily.
Safety & monitoring
- Common: nausea, diarrhea, abdominal discomfort, metallic taste
- Avoid if significant renal dysfunction (typically eGFR < 30)
- Hold around acute illness / iodinated contrast (lactic-acidosis risk)
- Monitor B12 with long-term use
Clinical pearl
Metformin mainly interrupts the insulin-resistance arm — it does not strongly target the hunger/reward circuits, so pair it accordingly.
Teaching message: right-size expectations. Great metabolic adjunct when IR/PCOS/T2DM coexist; weak as monotherapy for weight.
- Nuance: often used off-label for obesity — be transparent with families.
- Transition: the GLP-1 receptor agonists, where the modern story really turns.
1
Saxenda (liraglutide)
GLP-1 RA · once-daily SCTitration (daily): 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg (maintenance).
Peds obesityAge 12+, body weight > 60 kg AND obesity
2
Wegovy (semaglutide)
GLP-1 RA · once-weekly SCTitration (weekly): 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg (maintenance).
Peds obesityAge 12+ with obesity
Mechanism
- Slower gastric emptying
- ↑ satiation & satiety
- ↓ hunger & food preoccupation
- Improved glucose control
What the patient feels
- Smaller portions, earlier fullness
- Less snacking, less “food noise”
- Possible nausea (usually transient)
Safety
- Nausea, vomiting, constipation/diarrhea
- Gallbladder disease, pancreatitis risk
- Boxed warning: thyroid C-cell tumors — avoid with MTC or MEN2
Brand clarification
Ozempic is semaglutide but the diabetes brand — do not confuse it with Wegovy (obesity). A plateau does not necessarily mean drug tolerance.
Teaching message: the class that redefined obesity pharmacotherapy. Emphasise titration to limit GI effects, and the brand/molecule distinction.
- Nuance: boxed warning is class-wide; screen for MEN2/MTC history.
- Audience question: “Ozempic vs Wegovy — same molecule?” (yes; different brand/indication/dosing).
- Transition: the dual-agonist next step, tirzepatide.
How it works
Dual agonism of GIP and GLP-1 receptors → stronger satiety signalling, reduced hunger, slower gastric emptying, and major improvement in post-prandial glucose/lipid handling.
GIP + GLP-1
↓ hunger · ↑ satiety
Dosing & titration
- Start 2.5 mg SC once weekly × 4 weeks
- Then 5 mg once weekly
- ↑ by 2.5 mg every 4 weeks as tolerated, up to 15 mg
- Maintenance commonly 5, 10, or 15 mg
MOUNJARO
tirzepatide · T2DM. Indicated for adults and pediatric patients ≥10 y with type 2 diabetes.
ZEPBOUND
tirzepatide · obesity brand. Chronic weight management in adults with obesity, or overweight with ≥1 comorbidity.
Safety
- GI symptoms common (nausea, vomiting, diarrhea, constipation)
- Gallbladder disease, pancreatitis risk
- Boxed warning: thyroid C-cell tumors — contraindicated with MTC/MEN2
Do not conflate
Pediatric obesity approval is not the same as pediatric T2DM approval — and the brand is not the molecule.
Teaching message: dual incretin agonism, and the same brand-vs-indication trap as semaglutide. Titrate slowly.
- Nuance: Mounjaro (T2DM, has a pediatric age) vs Zepbound (obesity) — label by indication and jurisdiction.
- Transition: the remaining agents and precision therapy.
1
Orlistat
Irreversible intestinal lipase inhibitor- Does: ↓ dietary fat absorption
- Dose: 120 mg three times daily with fat-containing meals
- Effects: oily stool, urgency, flatulence
- Key: fat-soluble vitamin supplementation
2
Phentermine/Topiramate ER
Qsymia · central appetite- Peds obesity: age 12+
- Titrate: 3.75/23 → 7.5/46 → (if needed) 11.25/69 → 15/92 mg
- Effects: paresthesia, dry mouth, mood/cognitive, tachycardia
- Warning: teratogenic — avoid in pregnancy
3
Setmelanotide
IMCIVREE · biased MC4R agonist- Does: biased MC4R agonist (favours Gαq/MAPK) — restores melanocortin tone downstream
- For: POMC, PCSK1, LEPR deficiency, Bardet–Biedl syndrome; acquired hypothalamic obesity
- Effects: injection-site reactions, hyperpigmentation, mood/sexual effects
Precision therapy is genotype-directed — is it Layan's path today?
Setmelanotide is labelled only for specific monogenic/syndromic disease (POMC/PCSK1/LEPR, BBS, acquired hypothalamic obesity). Layan's picture is more consistent with common polygenic obesity with no current strong red flags, so she is not presently a setmelanotide candidate — genetic/secondary evaluation stays guided by extreme early-onset, marked hyperphagia, syndromic clues or hypothalamic injury, and is revisited over time.
Teaching message: beyond incretins — a mechanism-diverse toolkit. Setmelanotide is the flagship for precision (genotype-directed) obesity.
- Nuance: recognising monogenic phenotypes unlocks targeted therapy that generic drugs can’t match.
- Transition: when biology and drugs aren’t enough — surgery.
Foundation (non-negotiable, continues throughout)
Intensive health-behaviour & lifestyle treatment — sleep, screen time, sugar-sweetened-beverage reduction, activity, family-based support. Every medication is added to this base, never a replacement.
1 · Metformin
first medication · metabolic- Indicated by rising HbA1c + significant acanthosis (insulin resistance)
- Targets dysglycaemia / IR; modest weight effect
- Not a potent anti-obesity drug alone
2 · Semaglutide
approved adolescent obesity GLP-1 (≥12 y)- Her anti-obesity agent; weekly SC
- Titrate monthly to the therapeutic dose
- Also ≥12 y: liraglutide, Qsymia, orlistat · screen MTC/MEN2
Emerging
not a labelled adolescent obesity option- Tirzepatide = emerging / off-label in adolescents
- Zepbound = adult obesity · Mounjaro = T2DM ≥10 y
- Never conflate the two brands / indications
3 · Surgery
metabolic-bariatric (AAP 2023)- Refer ≥13 y when lifestyle ± Rx insufficient
- Class 3 (no comorbidity needed) — Layan qualifies
- Keep on the table; reassess longitudinally
Regulatory (US FDA), separate from physiology (Sperling 5e Ch.24): metformin peds T2DM ≥10 y (IR/dysglycaemia use per clinical judgement) · Wegovy peds 2022 · Saxenda peds 2020 · Qsymia peds 2022 · Xenical peds 2003 · Zepbound adult only / Mounjaro peds T2DM ≥10 y (2025) · Setmelanotide = monogenic/syndromic only · Surgery: AAP CPG 2023 (Hampl et al., Pediatrics). Confirm by jurisdiction & date.
The order, in one line
Lifestyle first; metformin for her rising glycaemia + acanthosis; then an approved GLP-1 (semaglutide, titrated) for the obesity itself; tirzepatide stays "emerging/off-label"; surgery is considered, not yet chosen.
Teaching message: translate the whole pharmacology section into one concrete, defensible plan for Layan without over-claiming.
- Foundation first: intensive lifestyle treatment is the base that every other step is added to — not an alternative to medication.
- Metformin is her first medication — driven by rising HbA1c + significant acanthosis (insulin resistance/dysglycaemia), not by weight alone; it is a metabolic adjunct, not a potent anti-obesity drug.
- Then the approved obesity agent: semaglutide (Wegovy) ≥12 y, titrated monthly to the therapeutic dose (liraglutide/Qsymia/orlistat also ≥12-labelled).
- Safety framing: tirzepatide is emerging/off-label in adolescents — Zepbound is adult-obesity, Mounjaro is pediatric T2DM (≥10 y). Never present a T2DM approval as an obesity approval.
- Surgery: she is 13 y with Class 3 obesity, so she meets the AAP 2023 age + BMI threshold for referral consideration if lifestyle ± pharmacotherapy is insufficient — framed as a longitudinal option, not an immediate step.
- Humility: a plateau later would be multifactorial (adherence, dose, sleep, biology) — reassess, don't assume tolerance.
09
Metabolic & Bariatric Surgery
Should Layan’s course ever lead here: surgery is not merely a smaller stomach. It rewires gut hormones and gut–brain signalling — a metabolic therapy.
The Core QuestionMicrophysiology of Hunger
How a Meal StopsHypothalamic Integration
Why Obesity DevelopsClinical Approach
Breaking the CyclePharmacotherapySurgery
Section 9 of 9. Reframe surgery from “restriction” to “metabolic reprogramming” — the key conceptual correction of this section.
Sleeve gastrectomy
Remove the gastric fundus → ↓ ghrelin, smaller capacity, earlier satiation, ↑ GLP-1 & PYY.
Roux-en-Y gastric bypass
Small pouch + rerouted intestine → ↑ GLP-1 & PYY, altered bile-acid signalling, improved insulin sensitivity.
Refer (adolescents) · AAP 2023
- Age 13+, when lifestyle/medical Rx insufficient
- Class 2 obesity + significant comorbidity, or
- Class 3 obesity (no comorbidity required)
Benefits
- Substantial weight loss (regain in a significant subset)
- Improved / remission of T2DM
- Improved OSA, hypertension, MASLD
- Better quality of life & function
Risks & commitments
- Leak, bleeding, surgical complications
- GERD (sleeve) · dumping (bypass)
- Gallstones · micronutrient deficiencies
- Lifelong follow-up & supplementation
Mechanism ≠ restriction
Surgery alters ghrelin, GLP-1, PYY, bile acids, gut–brain communication, insulin sensitivity, meal size, and eating behaviour — together.
The reframe
Surgery is a metabolic therapy that restores hormonal and functional balance — not just a mechanical size reduction.
Teaching message: the hormonal case for surgery — this is why it can induce diabetes remission out of proportion to weight lost.
- Nuance: patient experience shifts over time; adherence and structured follow-up are decisive.
- Transition: pull the whole story together.
Month 0
Diagnosis: Class 3 obesity, prediabetes, MASLD suspicion. Start intensive lifestyle treatment.
Month 6
No change, no improvement. HbA1c rising + significant acanthosis → start metformin (first medication).
Next visit
Poor compliance — she wasn't taking it, so no benefit. Address barriers; re-counsel the family.
~Month 12
She & family agree to semaglutide. Start low, increase monthly to the therapeutic dose, on top of lifestyle.
Ahead
If response stays inadequate: metabolic-bariatric surgery (she meets ≥13 y, Class 3) / endoscopic options — reassessed.
The follow-up lesson
Adherence is decisive — non-response is not automatically drug failure; check adherence, sleep, dose and environment first. Escalation is staged and reassessed, and a later plateau would be multifactorial (see Plateau ≠ tolerance), never a reason to abandon effective therapy.
Teaching message: Layan's journey is deliberately realistic, not idealised.
- Month 0: Class 3 obesity with prediabetes and MASLD suspicion — start intensive lifestyle as the foundation.
- Month 6: she returns with no change and no improvement; because her HbA1c is rising and she has significant acanthosis nigricans (insulin resistance), we start her first medication — metformin, targeting the metabolic complication rather than weight alone.
- Next visit: the honest reason for non-response is poor compliance — she wasn't taking the metformin. This is the single most important thing to check before declaring a drug ineffective; address barriers, cost, side-effect fears and family support.
- ~Month 12: after re-engagement, she and her family agree to start semaglutide, titrated upward monthly to the therapeutic dose, on top of continued lifestyle treatment.
- Ahead: if response remains inadequate, metabolic-bariatric surgery is on the table (she meets ≥13 y, Class 3) and is reassessed longitudinally.
- The lesson: escalation is staged and reassessed; adherence is decisive; and a future plateau would be multifactorial — not a reason to abandon effective therapy (ties to Plateau ≠ tolerance).
1
Hunger is biology, not willpower.
A regulated brain state driven by peripheral signals.
2
Satiation ends the meal; satiety delays the next.
Different clocks, different levers.
3
The hypothalamus integrates; reward can override it.
Cue-driven eating needs no energy deficit.
4
The body defends a weight range.
Regain and adaptation are physiology, not failure.
5
Every therapy breaks a specific node.
Match mechanism to phenotype; lifestyle underlies all.
6
Know the label, not just the molecule.
Pediatric obesity ≠ diabetes approval; brand ≠ drug.
Layan's journey: lifestyle → metformin → (once she engaged) semaglutide. Adherence was the turning point — biology is treatable with staged, reassessing care.
One sentence
Understand the circuit, and the whole ladder of treatment — from a slower meal to surgery — becomes one coherent story.
Closing. Recap the arc: signal → integration → defense → treatment. Invite questions.
- Audience question to leave them with: “For your next patient, which node will you target first — and why?”
Primary source
The physiology of energy balance, hormone signalling, obesity definitions/staging, and the clinical approach in this deck follow: Han JC, Weiss R. “Obesity, Metabolic Syndrome and Disorders of Energy Balance.” In: Sperling Pediatric Endocrinology, 5th ed. Elsevier; 2021: Chapter 24 (pp. 939–984).
Post-2021 therapies (e.g., semaglutide, tirzepatide, setmelanotide) and specific clinical thresholds draw on current prescribing information and pediatric obesity guidelines — confirm dosing, age indications, and warnings by jurisdiction and date.
DisclaimerThis presentation is intended for professional medical education and does not replace individualized clinical judgment, local regulatory labeling, or institutional protocols.
Aligned to Sperling 5e, Ch. 24 (Han & Weiss). Terminology, definitions, and causal logic follow that chapter; clinical specifics beyond it are drawn from current guidelines and labeling.
References slide. Keep citations off the main visual area; direct detailed questions to primary labeling.
Pediatric Endocrinology · Grand Rounds
Thank you
Hunger is biology — and biology is treatable.
Any Questions?
Close warmly and open the floor. Recap the one idea: hunger is a biological system, and every lever we discussed targets a real node in it.